| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
2,459 |
2,400 |
$246K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
1,977 |
1,939 |
$154K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
971 |
971 |
$140K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
979 |
979 |
$94K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,268 |
1,249 |
$64K |
| 87428 |
|
757 |
754 |
$22K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
109 |
108 |
$9K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
256 |
253 |
$9K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
249 |
249 |
$7K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
435 |
430 |
$6K |
| 99051 |
|
809 |
801 |
$5K |
| 87430 |
|
211 |
210 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
33 |
33 |
$2K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
14 |
14 |
$440.02 |
| 87400 |
|
33 |
33 |
$427.38 |